Background: Brain cancer (neuroblastoma) and liver cancer (hepatocellular carcinoma) are
common cancer types among others worldwide which do not have a radical treatment and cure.
Objective: In the current study, five novel pyridazinone derivates bearing benzelhydrazone moiety at
second position were synthesized and evaluated for their cytotoxic activity against neuroblastoma and
hepatocellular carcinoma (SHSY5Y and HEP3B) and human fibroblast (HF) cell lines. The aim of the
current study is to identify antiproliferative activity of five novel pyridazinone derivates against neuroblastoma
and hepatocellular carcinoma (SHSY5Y and HEP3B) and human fibroblast (HF) cell lines.
Method: The compounds were synthesized by the reacting 6-[4-(phenyl/4-chlorophenyl)piperazine-1-
yl]-3(2H)-pyridazinone-2-yl acetohydrazide with benzaldehyde in ethanol. The in vitro antiproliferative
activities were determined with MTT assay. Bax, Bcl-2 and Casp3 gene expression levels were detected
with RT-PCR analyses.
Results: The lowest IC50 was observed for compound 4 in SHSY5Y and HEP3B cells. Apoptosis increased
in cancer cells which was shown by changes inBax, Bcl-2 and Casp3 gene expression levels
with 1-5 compound therapy.
Conclusion: Novel pyridazinone derivates might be promising agents as new chemotherapeutic candidates
in brain and liver cancer.